Holen Sie sich die Stockscreener-App
79.02
0.79%
-0.63
Handel nachbörslich:
79.00
-0.02
-0.03%
Schlusskurs vom Vortag:
$79.65
Offen:
$80.29
24-Stunden-Volumen:
1.38M
Relative Volume:
0.63
Marktkapitalisierung:
$15.28B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-21.59
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-2.14%
1M Leistung:
+4.93%
6M Leistung:
+112.48%
1J Leistung:
+79.59%
1-Tages-Spanne:
$77.86
$80.47
1-Wochen-Bereich:
$77.86
$80.92
52-Wochen-Spanne:
$29.17
$81.97
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
79.02 | 15.40B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Free Popular Stock Picks Selection - earlytimes.in
Harbor Capital Advisors Inc. Has $1.01 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
What sentiment indicators say about Revolution Medicines Inc. stockLong-Term Investment Plans & Access Free Risk Analysis Before You Invest - Bollywood Helpline
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Extending Long-Term Upside Potential - TipRanks
Revolution Medicines stock hits all-time high at 81.49 USD By Investing.com - Investing.com Nigeria
Understanding Momentum Shifts in (RVMD) - news.stocktradersdaily.com
Revolution Medicines (NASDAQ:RVMD) Hits New 52-Week HighHere's What Happened - MarketBeat
Revolution Medicines stock hits all-time high at 81.49 USD - Investing.com
How resilient is Revolution Medicines Inc. stock in market downturns2025 Price Targets & Long-Term Growth Stock Strategies - ulpravda.ru
Trend Review: Will Revolution Medicines Inc. stock deliver long term returnsMarket Risk Report & Scalable Portfolio Growth Methods - ulpravda.ru
Why ETFs are accumulating Revolution Medicines Inc. (42Z) stockQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - DonanımHaber
How Revolution Medicines Inc. stock valuations compare to rivalsWeekly Profit Recap & Capital Protection Trading Alerts - DonanımHaber
Is Revolution Medicines Inc. stock positioned for digital transformationJuly 2025 Earnings & Detailed Earnings Play Alerts - DonanımHaber
Is Revolution Medicines Inc. stock positioned well for digital economyMarket Performance Report & Stepwise Trade Execution Plans - DonanımHaber
Can Revolution Medicines Inc. stock weather global recession - DonanımHaber
Why Revolution Medicines Inc. Equity Warrant stock could outperform in 2025Earnings Growth Report & Low Risk High Reward Ideas - Улправда
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 15,394 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 3,104 Shares - MarketBeat
Revolution Medicines Insider Sold Shares Worth $1,182,526, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines (RVMD) General Counsel reports Form 4 stock sale - Stock Titan
Revolution Medicines (RVMD) CEO Goldsmith discloses 15,394-share tax-related sale - Stock Titan
[Form 4] Revolution Medicines, Inc. Insider Trading Activity - Stock Titan
Revolution Medicines (RVMD) COO reports 4,847-share sale under Rule 10b5-1 plan - Stock Titan
Revolution Medicines (RVMD) CFO reports 3,104-share sale under 10b5-1 plan - Stock Titan
Revolution Medicines Says First Patient Randomized in Phase 3 Pancreatic Cancer Trial - marketscreener.com
Revolution Medicines (RVMD) Launches Key Phase 3 Trial for Pancr - GuruFocus
Revolution Medicines randomizes first patient in Rasolute-304 trial - marketscreener.com
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy - The Manila Times
Breakouts Watch: How Revolution Medicines Inc. Equity Warrant stock responds to policy changesJuly 2025 Macro Moves & Real-Time Volume Analysis - Улправда
Revolution Medicines (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 5,447 Shares - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts - MarketBeat
HRT Financial LP Increases Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Holocene Advisors LP Lowers Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Bellevue Group AG Purchases 205,000 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Officer Kelsey Files To Sell 5,296 Of Revolution Medicines Inc [RVMD] - TradingView — Track All Markets
CFO Anders Files To Sell 3,017 Of Revolution Medicines Inc [RVMD] - TradingView — Track All Markets
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - biocentury.com
Avoiding Lag: Real-Time Signals in (RVMD) Movement - news.stocktradersdaily.com
FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD) - Yahoo Finance
Delphia Therapeutics Appoints Steve Kelsey, M.D., To Board - citybiz
Revolution Medicines (NASDAQ:RVMD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Sold by Hood River Capital Management LLC - MarketBeat
New York State Common Retirement Fund Grows Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) up 27.9% since last earnings report: Can it continue? - MSN
Norges Bank Invests $62.58 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
State Board of Administration of Florida Retirement System Acquires 30,128 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? - sharewise.com
Will Revolution Medicines Inc. Equity Warrant stock split attract more investors2025 Retail Activity & Weekly High Momentum Picks - Newser
Why Revolution Medicines Inc. Equity Warrant stock is favored by pension fundsJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - Newser
Russell Investments Group Ltd. Sells 86,034 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Why hedge funds are buying Revolution Medicines Inc. Equity Warrant stock2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Revolution Medicines Inc-Aktie (RVMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOLDSMITH MARK A | See Remarks |
Dec 16 '25 |
Sale |
76.82 |
15,394 |
1,182,526 |
232,469 |
| Kelsey Stephen Michael | See Remarks |
Dec 16 '25 |
Sale |
76.82 |
5,447 |
418,423 |
278,600 |
| Horn Margaret A | Chief Operating Officer |
Dec 16 '25 |
Sale |
76.82 |
4,847 |
372,333 |
141,053 |
| Anders Jack | Chief Financial Officer |
Dec 16 '25 |
Sale |
77.09 |
3,104 |
239,289 |
108,065 |
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):